Table 5 Comparison of designs and findings of previous primary brain tumour prevalence surveys
Study, date, reference | Region | Population | Prevalence date | Design | Diagnosis | Prevalence (1/100,000) | Subgroup/subtype (1/100,000) |
|---|---|---|---|---|---|---|---|
Wang, 1985 [10] | China | All ages; 65,067 in urban areas including six cities in China | Jan 1, 1984 | Cross-sectional survey, point prevalence | Clinical diagnosis; histology; imaging | 32 (20.91–43.09) | -- |
Li, 1989 [11] | China | All ages; 246,812 people in rural areas of 21 provinces in China | Jan 1,1985 | Cross-sectional survey, point prevalence | Clinical diagnosis; histology; imaging | 6.9 (1.75–12.05) | Men, 7.3; women, 6.4 |
Jiang, 2011 [14] | China | All ages; 2,589,448 people in five cities in China | 2006 | Registry of primary brain tumours, period prevalence | Clinical diagnosis; histology; imaging | 24.56 (14.85–34.27) | Men, 18.84 (10.33–27.35); women, 30.57 (19.73–41.41) |
Davis, 2001 [2] | USA | All ages; no data on population | 2000 | Prevalence rates were estimated using age-specific incidence rates (1985–1994) and survival curves from two population-based tumour registries from the Central Brain Tumor Registry of the United States in a statistical model. | Behavior codes; histology | 130.8 | Benign, 97.5; malignant, 29.5 (men, 32.7; women, 25.9) |
Porter, 2010 [3] | USA | All ages; no data on population | 2004 | An estimate of the prevalence of disease in the United States based on incidence data for 2004 and survival data for 1985–2005 obtained by the Central Brain Tumor Registry of the United States from selected regions for the year 2004. | Histology | 209 | Men, 158.7; women, 264.8; glioma, 34.3 |
Porter, 2010 [3] | USA | All ages; no data on population | 2010 | A projected estimate of the prevalence of disease in the United States based on incidence data for 2004 and survival data for 1985–2005 obtained by the Central Brain Tumor Registry of the United States from selected regions for the year 2010. | Histology | 221.8 | -- |
Crocetti, 2012 [4] | Europe | All ages; 2008 European population (497,455,033) | Jan 1, 2003 | Point prevalence at the index date estimated based on incidence and follow-up data from 22 population-based cancer registries; | Cancer registries coded according to ICD-O-3 | -- | Glial tumour of CNS, 26.3; non-glial tumour of CNS and pineal gland, 4.7 |
Adami, 1989 [15] | Sweden | All ages; 8.3 million inhabitants constituting the Swedish population | Dec 31, 1984 | National Swedish Cancer Registry, point prevalence | Clinical diagnosis; histology | -- | Men, 68; women, 93 |
Daly, 2006 [16] | Belgium | All ages; 71972 inhabitants in Belgium | Sep 30, 2005 | Cross-sectional hospital-based clinic review, point prevalence | Clinical diagnosis; histology; hormonal workup | -- | Pituitary adenoma, 94 (72.2–115.8) |
Fernandez, 2010 [17] | Banbury, Oxfordshire, England | All ages; 81149 inhabitants in Banbury | Jul 31, 2006 | Cross-sectional administrative database, point prevalence | Clinical diagnosis; histology; hormonal workup | -- | Pituitary adenoma, 77.6 |
Colonna, 2008 [18] | France | All ages; whole French population; no data on population | 1998–2002 | Incidence and survival data from French cancer registries were used to estimate specific 5-year partial prevalence rates | Cancer registries coded according to ICD-O-3 | -- | Men, 13.8; women, 15.9 |